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Breast milk is the nutrition of choice for human infants (American Academy of Pediatrics,
2005; American Association of Family Physicians, 2008; Association of Women’s Health
Obstetric and Neonatal Nurses, 2005; Canadian Paediatric Society, 2005; U.S. Preventive
Services Task Force, 2008; World Health Organization, 2009). The literature on the benefits
of breast milk and breastfeeding for infants and mothers has established multiple positive
outcomes for infants (Hoddinott, Tappin, & Wright, 2008; Horta, Bahl, Martines, & Victora,
2007; Ip et al., 2007). Breast milk has advantages for infants that distinguish it from
standard commercial infant formulas. These advantages include growth factors, hormones,
immunological factors, and long-chain polyunsaturated fatty acids. For infants with
phenylketonuria (PKU), breast milk has additional advantages over any standard
commercial infant formula, such as a lower concentration of protein and a lower content of
the amino acid, phenylalanine. Despite these benefits, some clinics encourage mothers of
infants with PKU to breastfeed whereas others present breastfeeding as an unacceptable
option. Although the possible risks and benefits of breastfeeding infants with PKU have
been discussed, there is limited research and practice describing breastfeeding infants with
PKU. As a result, breastfeeding infants with PKU is based more upon limited clinical
experiences rather than upon evidence based practice that aims to apply the best scientific
evidence gained from research to clinical decision making.
Review of the Literature
Phenylketonuria is an autosomal recessive genetic disorder that, although most common in
people of Northern European heritage, is found in all ethnic groups (Donlon, Levy, &
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Scriver, 2007; Kaye, & Committee of Genetics, 2006; Meyers, 2002). In classic PKU, there
is a metabolic block that prevents the conversion of phenylalanine (Phe) to tyrosine (Tyr) in
the normal metabolism of protein within the liver (Jervis, 1953) (See Figure 1). Excessive
Phe accumulates in the blood and tissues as a toxic metabolite that damages central nervous
system cells resulting in progressive and irreversible cognitive deficits (Huttenlocher, 2000;
Malamud, 1966; Scriver, Levy, & Donlon, 2008).
Prior to newborn screening for PKU, the disorder was diagnosed from classical clinical
manifestations that became apparent over time. These manifestations included: normal
development at birth but failure to attain early developmental milestones; excessively fair
hair, skin, and eyes; and a “musty” odor of skin, hair, perspiration, and urine. By the time
the infant was diagnosed, impairment of cerebral function had already occurred
(Huttenlocher, 2000; Malamud, 1966; Scriver et al., 2008). Today, PKU diagnosis is made
soon after birth from results of newborn screening tests and treatment begins immediately
(Dhondt, 2007; Guthrie, & Susi, 1963; Therrell, & Adams, 2007). The treatment of PKU
involves a lifelong diet low in Phe, frequent monitoring of blood Phe values and regular
consultation with the pediatric metabolic team of physicians, nurses, and dieticians. Normal
cognitive development is expected when Phe blood levels are managed and remain within
acceptable levels (120–360μmol/L) (Cummings, 2008; de Baulny, Abadie, Feillet, & de
Parscau, 2007).
In the early years of PKU treatment, the standard of care for infants diagnosed with PKU
was to be immediately weaned from breastfeeding. To maintain appropriate Phe levels
(120–360μmol/L), the infant was then placed on a diet of Phe-free or low-Phe formula
combined with standard commercial infant formula (Ernest, McCabe, Neifert, & O’Flynn,
1980; Huner, & Demirkol, 1996; McCabe et al., 1989; Motzfeldt, Lilje, & Nylander, 1999).
This combination was believed to be the only effective way to monitor the infant’s intake
and allow for precise titration and measurement of the intake of Phe in order to protect the
infant’s neurological and cognitive development (Blau, Duran, & Gibson, 2008). Mothers of
infants with PKU titrated Phe-free formula with standard commercial formula based on Phe
levels obtained from infant heel sticks. This management strategy thus precluded
breastfeeding infants with PKU (Ernest et al., 1980; Huner, & Demirkol, 1996; McCabe et
al., 1989; Motzfeldt et al., 1999).
In the late 1970’s, researchers determined that breast milk was lower in Phe than standard
commercial formula (Janas, Picciano, & Hatch, 1985; Lonnerdal, Forsum, Gebre-Medhin, &
Hambraeus, 1976; Nayman, Thomson, Scriver, & Clow, 1979). Thus, a larger volume of
breast milk than standard commercial infant formula could be fed to infants with PKU. In
1980, the first publication appeared describing breastfeeding infants with PKU (Ernest et al.,
1980). Subsequent research on bottle-fed infants with PKU compared to breast-fed infants
with PKU during the first six months, showed that those infants with PKU who had been
breast-fed and supplemented with Phe-free formula had lower protein and Phe levels (van
Rijn et al., 2003). In addition, combining breast milk and Phe-free formula in managing the
diet of infants with PKU did not adversely affect Phe control (Greve, Wheeler, Green-
Burgeson, & Zorn, 1994; McCabe et al., 1989). In more recent studies, breast-fed infants
with PKU had no significant differences in weight gain, daily Phe intake, and the mean
plasma Phe concentrations compared to formula-fed infants with PKU (Cornejo et al., 2003;
Demirkol et al., 2001; Huner, Baykal, Demir, & Demirkol, 2005; Kanufre et al., 2007;
McCabe et al., 1989; Motzfeldt et al., 1999; van Rijn et al., 2003). Although based on
relatively small samples (usually < 50 participants) reflecting the rarity of PKU in the
population, the results from these studies consistently supported the conclusion that breast
milk supplemented with Phe-free formula is an acceptable dietary treatment for infants with
PKU.
Despite evidence that breast milk is compatible with effective dietary management of PKU,
the majority of breastfeeding studies in PKU are studies of the incidence of breastfeeding in
infants with PKU and consistently showed that few mothers of infants with this condition
persist in breastfeeding. For example, an Italian study identified one-year breastfeeding rates
were significantly lower in infants with PKU than in the general population (Agonstoni,
Verduci, Fiori, Riva, & Giovannini, 2000). Most recently, only 19 of 35 Brazilian mothers
were found to be breastfeeding at 6 months and only 11 of these mothers continued to
breastfeed at 12 months (Kanufre et al., 2007).
The duration of breastfeeding is also shorter for infants diagnosed with PKU. In Norway,
where breastfeeding is the norm with 92% of mothers exclusively breastfeeding during the
first three months and 40% continuing to breastfeed to infant age of 15 months (World
Health Organization, 2007), mothers breast-fed their infants with PKU (n = 74) for a mean
duration of 7 months (Motzfeldt, Lilje, & Naylander, 1999). In another study, breast-fed
infants with PKU (n = 39) were identified to have a shorter mean duration of 4 months
(Segev, Abraham, Anikster, & Schwartz, 2004) as did a Dutch study at 2.5 months (van Rijn
et al., 2003) and the Italian study with a median of 1 month (Agostoni, Verduci, Fiori, Riva,
& Giovannini, 2000). In two Turkish studies, the mean duration of breastfeeding by mothers
of infants with PKU was higher with one group breastfeeding for a mean of 9.6 months (n =
40; Demirkol et al., 2001) while the other breast-fed for a mean duration of 10.8 months (n =
13; Hunter & Demirkol, 1996), overall, mothers with infants with PKU tend to breastfeed
for a shorter period of time than mothers of infants without PKU.
Notably, there are no published studies of the incidence or duration of breastfeeding infants
with PKU conducted in the United States. Therefore, the purpose of this study was to
compare the incidence and duration of breastfeeding and corresponding Phe levels of breast-
fed and formula-fed infants with PKU in the caseload of a pediatric metabolic clinic at an
urban tertiary-care medical center in the United States. Our first objectives were to
determine the incidence of breastfeeding at the time of diagnosis, determine the duration of
breastfeeding after infants were diagnosed, determine Phe control during the period of
breastfeeding, and compare Phe values between breast-fed and formula-fed infants with
PKU.
Methods
The study design was a retrospective chart review performed at an urban, tertiary-health care
center with two hospitals, an adult hospital and a children’s hospital. Serving Oregon and
Southwest Washington, the two hospitals had combined inpatient beds of 560. The
children’s hospital is dedicated to the care of children and their families, and includes a 20
bed pediatric intensive care unit and a 46 bed neonatal intensive care unit. In addition, the
children’s hospital has the only pediatric metabolic clinic program in the state, to which all
infants diagnosed with PKU are referred.
The retrospective chart review took place from 2006 through 2008 following institutional
review board approval. Medical records for infants diagnosed with PKU were reviewed
beginning with 2005 and ending with 1980, the year when no further breastfeeding cases in
the PKU population were identified. Specifically, infants’ medical, dietary, and clinical
records that provided assessments of the infant from both dietitian and medical perspectives,
as well as serial information on the Phe levels over time, provided the data.
The data were collected using a medical record abstraction tool for recording data and
recording data were limited to those variables needed to address the study objectives (i.e.,
dates of serial Phe levels and mode of feeding). In addition, demographic data were
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collected on the infant. Phe results that had been reported from newborn screening and
follow up serial Phe results in the past were documented. No newborn screen bloodspots
were accessed or retested. The frequency of measuring plasma Phe levels with Guthrie
cards, specific filter paper onto which blood from a heel-prick is saturated, is depended on
the infant’s age and Phe tolerance. Generally, the frequency that Phe levels were assessed
ranged from every other day to twice a week when levels were stable within the
therapeutically aimed range (120–360 μmol/l). Between 1980 and 2002, plasma Phe levels
were determined using an amino acid analyzer. During 2002, the laboratory transitioned to
tandem mass spectrometry to determine Phe analytes, and this method was used through
2005. The use of tandem mass spectrometry has improved the detection of inborn errors of
metabolism with improved sensitivity and specificity of newborn screening for amino acid
disorders, such as PKU.
Infants were categorized as breast-fed or bottle-fed from the medical record, in which the
type of feeding was noted with the serial Phe levels. Breastfeeding/breast-fed was defined as
an infant with PKU who received breast milk either directly from the breast or as expressed
breast milk delivered from a bottle, and received Phe-free formula from a bottle to maintain
appropriate Phe levels. Bottle-feeding/bottle-fed was defined as an infant with PKU who
received all sources of nourishment, including standard commercial infant formula and Phe-
free formula, from a bottle. The date breastfeeding was terminated was determined in two
ways. The date that the last breastfeeding was recorded was taken as the end date of
breastfeeding or, alternatively, the date that breastfeeding was terminated was located in the
dietitian’s record. If this latter date was the most precise, it was accepted over the first.
Statistical analyses were conducted using SPSS 16 (SPSS Corporation, Chicago, IL). Data
were analyzed using descriptive statistics, chi square and ANOVAs as appropriate.
Sample
Charts were reviewed for all newborns who were screened positive for PKU, confirmed by
laboratory analysis, and began medical and dietary management of PKU at the pediatric
metabolic clinic between 1980 and 2005. Of the 102 infants diagnosed with PKU during
these 25 years, the data for 97 infants were retained for analysis. Five were eliminated due to
fewer than five Phe levels during the first year, transfer of care to another metabolic clinic,
or transfer from another metabolic clinic prior to one year of age. Of the 97 infants with
complete data managed by the Pediatric Metabolic Clinic during the study period, 75 infants
were breast-fed for varying lengths of time after their diagnosis and 22 infants were bottle-
fed. The proportion of males (n = 48; 50%) and females (n = 49; 51%) was comparable to
that of other autosomal recessive disorders. Most of the infants had normal birth weights.
Gestational age was not systematically recorded, but the birth weights suggested that these
infants were born at term as birth weights were of normal range and indicative of full term
births. The infant characteristics of both groups are presented in Table 1; there were no
significant differences between the breast-fed and bottle-fed infants with PKU.
Results
Incidence of Breastfeeding at Time of Diagnosis
The overall initiation rate for breastfeeding of infants (n = 75) with PKU was 77%. The
incidence of breastfeeding at the time of diagnosis by decade for infants diagnosed with
PKU consistently exceeded the Healthy People 2000 and 2010 breastfeeding objective for
initiation of breastfeeding (Tables 2 and 3). During the 1980’s, the incidence of
breastfeeding at the time of diagnosis was 72%. This slightly decreased during the 1990’s to
70%. However from 2000 to 2005, the incidence of breastfeeding at the time of diagnosis
increased to 87%. These levels of breastfeeding not only consistently exceeded the
breastfeeding initiation rates established by Healthy People objectives, but the national and
state initiation rates at those times.
Duration of Breastfeeding for Infants with PKU
The mean duration for breastfeeding infants with PKU from 1980 to 2005 was 6.8 months.
Every decade, there were mothers who initiated breastfeeding, but stopped within one month
(n = 16, 21%). The maximum breastfeeding duration for breastfeeding infants with PKU
between 1980 and 1989 was 24 months with a mean of approximately 9 months. For
breastfeeding infants with PKU between 1990 and 1999, the maximum duration decreased
to 16 months with a mean of 5 ½ months. Between 2000 and 2005, breastfeeding duration
increased from the previous decade for breast-fed infants with PKU to a maximum of 23
months with a mean of 6 months.
Breast-fed infants with PKU in this study successfully met the Healthy People 2000 six
month objective from 1980 to 1989 (Tables 2 and 3). Mothers breastfeeding infants with
PKU from 1990 to 2005 did not met the Healthy People 2000 or 2010 breastfeeding
objective for six months. In addition, the mothers from 1980 to 1989 almost met the Healthy
People 2000 breastfeeding objective at twelve months (15% vs goal of 16%) while mothers
breastfeeding infants with PKU from 1990 to 2005 did not meet the Healthy People 2000 or
2010 twelve months breastfeeding objective.
Comparison of Phe Values
To calculate the mean Phe level while breastfeeding and formula-feeding, each infant was
required to have at least five Phe levels; typically, these were in addition to the two newborn
screen results and confirmatory test which were elevated and skewed the data. These
diagnostic elevated Phe levels were eliminated from the analysis. The mean Phe levels while
breastfeeding and formula feeding are presented in Figure 2. Eighty percent (n = 59) of the
breast-fed infants with PKU and 77% (n = 22) of the bottle-fed infants with PKU had mean
Phe values within the desired treatment range (120–360μmol/l). The mean Phe levels were
then categorized into low, normal and high mean Phe levels. As shown in Figure 3, there
was a significant association between type of feeding and category of mean Phe level, χ2 (2,
N = 3,260) = 205, p < .001. Specifically, breastfed babies were more likely to have a normal
mean Phe level and therefore successful management of PKU. Bottle-fed babies were more
likely to have a low mean Phe level and the two groups were comparable in their
distribution in the high mean Phe level category. Both low (< 120μmol/l) and high (>
360μmol/l) Phe levels reflect poor management of PKU.
Given that the pediatric metabolic clinic was the only clinic in the state for the management
of PKU, a posthoc analysis was conducted to ascertain whether management of the Phe level
differed by proximity to the clinic or region of the state. Breast-fed and bottle-fed infants
with PKU were categorized as living within the metropolitan area where the clinic was
located or living outside the metropolitan area. There was a significant association between
type of feeding and location within or outside the metropolitan area and for attaining a
normal mean Phe level (120–360μmol/l), χ2 (1, N = 1,685) = 18.56, p < .001. Breast-fed
infants living in the metropolitan area were more likely to be in the normal mean Phe level
category; and outside the metropolitan area, bottle-fed infants outside the metropolitan area
were more likely to be in the normal mean Phe level category (Figure 4). When assessed in
relation to the low mean Phe level and in relation to the high mean Phe category, type of
feeding and location were not significantly associated.
Further post-hoc analysis of regional data shown in Figure 5 revealed regional differences in
the mean Phe values; regions are listed in order of approximate progressive distance from
the metropolitan area where the pediatric metabolic clinic is located. The Central High
Mountain Desert and the Coastal regions had significantly higher mean Phe levels than the
metropolitan and other regions, F(6, 2251) = 5.2, p < .001. As the metropolitan area has a
lower percent of uninsured families compared to the rest of the state, an analysis was
performed to evaluate if there was any difference between Phe control and form of family
medical insurance. Medical insurance was categorized as private, state Health Plan, adjacent
state health plan, and self-pay. The 95% confidence intervals (CIs) for each independent
variable were derived through regression analysis and were not significant.
Discussion
These results were remarkable considering that mothers of infants with PKU who were
breastfeeding were also managing the disorder of PKU. These mothers were not only
meeting the Healthy People breastfeeding objectives, but at times surpassing them for
breastfeeding initiation and continuation rates at six months. Oregon has one of the nation’s
highest breastfeeding rates and was the first state to meet the Healthy People 2010
breastfeeding objectives. The State of Oregon actively encourages breastfeeding within the
Office of Family Health with the program, Breastfeeding Promotion. Oregon law requires
employers to offer lactation consultation and support to breastfeeding mothers and has
legislation to protect mothers’ right to breastfeed in public. In Oregon, breastfeeding is the
norm and this norm has been clearly extended to mothers of infants with PKU even in the
face of challenges to maintain therapeutic Phe levels.
Mothers’ breastfeeding infants with PKU consistently surpassed initiation of breastfeeding
objectives for Healthy People 2000 and 2010. Not only did these mothers surpass the
initiation rates from 1980 to 1999, but they also exceeded the rate at six months for the
nation. However, over time, mothers of breast-fed infants with PKU varied in meeting the
breastfeeding objective for six months duration from 38% (1980’s) to 24% (1990’s) to 30%
(2000’s). Except for the 1980’s, there was a decline of fifty percent or more of breastfeeding
at six months. In addition, there was another steep decline in breastfeeding at twelve months
from 15% (1980’s) to 4% (1990’s) to 5% (2000’s). Although there has been progress in
Oregon for breastfeeding infants with PKU, these data may not reflect the breastfeeding rate
in the rest of the nation. In addition, little is known about how mothers manage
breastfeeding infants with PKU and what contributes to the decline that begins at six months
and accelerates at twelve months.
During the first year of life, the majority of infants, whether breast-fed or bottle-fed, had
similar mean Phe levels. Overall, more breast-fed infants with PKU had Phe levels within
the normal range (120–360μmol/L) and were less likely to have a low Phe levels
(<120μmol/L) especially in the metropolitan area. This finding supports previous research
that breast-fed infants with PKU can have Phe levels within the desired therapeutic range
(Cornejo et al., 2003; Huner, & Demirkol, 1996; Kanufre et al., 2007; McCabe et al., 1989;
van Rijn et al., 2003). These mothers were effectively managing their infant’s Phe levels,
successfully managing the disorder of PKU, and breastfeeding their infants with PKU.
Further research is needed to understand how mothers manage breastfeeding in the context
of PKU. If breastfeeding management for mothers of infants with PKU is understood, it can
be taught and breastfeeding could be encouraged in other parts of the country where
breastfeeding is not the norm.
We can only hypothesize why infants with PKU living in the Central and Coastal regions of
Oregon have significantly higher mean Phe levels. One possible cause might be due to
difficulty of access to the tertiary clinic as there are no direct roads over both the Cascade
and Coastal Mountain Ranges along with the termination of train and bus services to these
rather remote areas of the state. Other possibilities could be due to a lack of professional
support with lactation knowledge about breastfeeding infants with PKU within those two
regions or parental understanding of the management of PKU and the need to maintain
normal mean Phe level (120–360μmol/l). Clearly more research is needed to clarify why
infants with PKU living in these areas have consistently higher Phe levels and how to
change this trend so that Phe levels are in the normal therapeutic range.
Limitations
This research has the limitations that are inherent to retrospective studies with small unique
populations. In this study, the population was cared for in one clinical metabolic program. In
addition, descriptive data to further evaluate breastfeeding and Phe levels were not
systematically documented in the medical records over the 25 years covered in the study.
For example, there was incomplete documentation of maternal characteristics such as race,
age, marital status, and level of education, variables typically positively linked to
breastfeeding initiation rates and duration rates. Other variables negatively associated with
breastfeeding, such as smoking and returning to employment, were also not systematically
documented. In addition, there was insufficient documentation to determine which mothers
qualified for the Special Supplemental Nutrition Program for Women, Infants and Children
(WIC) that encourages breastfeeding among its participants.
Future Research
The results of this study clearly provide evidence that mothers are capable of breastfeeding
infants with PKU and maintaining normal therapeutic Phe levels. It is possible mothers who
were able to persist with the challenges of simultaneously managing breastfeeding and PKU
were more motivated to continue breastfeeding. Further research is needed to explore the
variables that are associated with successfully breastfeeding infants with PKU as it is
unknown if these variables are the same characteristics that have been associated with
successful breastfeeding in other populations, such as healthy term infants and premature
infants (Forster, McLachlan, & Lumley, 2006; Thulier, & Mercer, 2009; Zachariassen et al.,
2010). In addition, it is unknown what factors predict a more successful duration of
breastfeeding infants with PKU. There also are no studies that retrospectively or
prospectively examine specific reasons for early cessation of breastfeeding infants with
PKU. Moreover, it is unknown what resources help mothers’ to successfully breastfeed
infants with PKU. Mothers of infants with PKU could need more intensive, individualized
support during the early weeks after diagnosis of PKU and later as low-Phe table foods are
introduced. Further research into these aspects will provide knowledge that is needed to
develop interventions that will help mothers continue to breastfeed infants with PKU, to
support their breastfeeding goals, and to increase breastfeeding durations recommended by
Healthy People objectives.
Clinical Implications
Breastfeeding can be successful provided in the management of infants with PKU while
maintaining normal therapeutic Phe levels. The infants’ success reflects the success of their
mothers’ efforts to manage breastfeeding in this unique and challenging context. Mothers
with breastfeeding infants who have PKU and who had planned to breastfeed should be
supported and encouraged to continue breastfeeding. Nurses need to determine mothers’
breastfeeding goals, and identify mothers’ available supports when planning and providing
metabolic guidance in managing their infant’s Phe levels. Lastly, it is imperative that nurses
who provide metabolic care to mothers of infants with PKU reinforce mothers’ breast milk
remains the optimal base feeding for their infants with PKU.
Summary
Data gleaned from this study serve to document that breastfeeding success is possible for
mothers with infants who have PKU and Phe levels can optimally be managed when
breastfeeding. Further research is needed to explore how these mothers successfully
maintain breastfeeding in the context of managing the disorder of PKU for their infants.
Such research will contribute to the identification of effective strategies for the clinical
management of breastfeeding and PKU.
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Figure 1. Simplified phenylalanine pathway in PKU
Figure 2. Mean Phe level for each infant by birth year
The shaded area between 120 μmol/l and 360 μmol/l represents the normative range for Phe
levels for infants with PKU, and therefore, successful management of PKU.
Figure 3. Frequency Differences between Breast-fed and Bottle-fed Infants with PKU and the
Probability of having a Normal (120–360 μmol/l), Low (<120 μmol/l) or High (>360μmol/l) Phe
Levels
* = χ2 (df = 2, N = 3,260) = 205, p < .001
Figure 4. Comparison between Breast-fed and Bottle-fed Infants with PKU living in the
metropolitan area vs non-metropolitan area and the Probability of having a Normal Phe Level
Metropolitan area includes the three counties of Clackamas, Multnomah, and Washington
which designates the Portland metropolitan area. The non-metropolitan area included the
following regions: Willamette valley, central high mountain desert, mountainous southern,
coastal, rural eastern, and adjacent southern region of the state of Washington. The shaded
area between 120 μmol/l and 360 μmol/l represents the normative range for Phe levels for
infants with PKU, and therefore, successful management of PKU. * = χ2 (df = 1, N = 1,685)
= 18.56, p < .001
Figure 5. Regional Difference in the mean Phe Levels
The shaded area between 120 μmol/l and 360 μmol/l represents the normative range for Phe
levels for infants with PKU, and therefore, successful management of PKU. * = significant,
F(6, 2251) = 5.2, p < .001
Table 1
Baseline infant characteristics
Breast-fed (n = 75) Formula-fed (n = 22)
Age in days at diagnosis 15 (5–65)a 17 (6–44)a
Plasma Phe level at diagnosis (μmol/l) 1,126.8 (240–3,534)a 1,339.8(480–2,802)a
Birth weight (kg) 3.46 (2.05–5.3)a 3.66 (1.5–5.2)a
Gender (M/F) 39M:36F 9M:13F
aNumbers represent means with ranges min/max are given in parentheses.
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Table 3
Incidence and Duration of Breastfeeding Infants with PKU, 2000–2005
Duration of Breastfeeding
Healthy People
2010 Objectivesa
Breastfeeding PKU Infants,
2000–2005 (n=20)
National US
Breastfeeding 2005b Oregon Breastfeeding 2005b
Initial postpartum 75% 87% (n = 20) 74% 86%
6 months 50% 30% (n = 6) 43% 60%
12 months 25% 5% (n = 1) 21.5% 37%
aU.S. Department of Health and Human Services. (2000). Healthy People 2010: National Health Promotion and Disease Prevention Objectives.
Retrieved from http://healthypeople.gov/.
bCenter for Disease Control. (2005). Final geographic-specific breastfeeding rates among children born in 2005. Retrieved from
http://www.cdc.gov/breastfeeding/data/NIS_data/2005/state_any.htm
